Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

By K. Cahill, S. Stevens, R. Perera, T. Lancaster. Cochrane Database of Systematic Reviews, 2013

1,215 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. (2016, neutral): “A recent open-label trial in lighter smokers(17) further highlights the need for doubleblind, placebo-controlled, head-to-head comparisons as evidenced by that study’s results being inconsistent with previous findings of meta-analyses that varenicline was more efficacious than single formulation nic”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “The partial nicotine receptor agonist varenicline at the standard dose increases the chances of quitting more than two-fold compared with placebo (14 trials, 6166 people).(283) The number of people stopping smoking with varenicline is higher than with bupropion (three trials, 1622 people).”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “The partial nicotine receptor agonist varenicline at the standard dose increases the chances of quitting more than two-fold compared with placebo (14 trials, 6166 people).(283) The number of people stopping smoking with varenicline is higher than with bupropion (three trials, 1622 people).”